Nutrition Health Chat: Tuesday, Dec. 8th, 5-6 PM Eastern. Learn how vitamins, minerals, and phytonutrients affect your health. Free live Q&A. Join us!
Member Comments are provided by individuals and reflect their personal opinions only. Under NO circumstances should you act on any advice or opinion posted in this forum. ALWAYS check with your personal physician before taking any action regarding your health! MedHelp International and our partners, sponsors and affiliates have no obligation to monitor any comments posted on this site, or the content and/or accuracy of such exchanges. MedHelp International does not endorse the views of any user.
Hep C TX, neutropenia and Meloxicam
by Proactive, Dec 04, 2008 03:17PM
Funny, was researching Meloxicam (I'm now taking it for osteo) because of it's possible adverse side effects on the liver and low and behold, found this. Do remember it being posted here, but it might have been..
Hepatology Research, T.
Kagawa and colleagues assessed
whether the nonsteroidal
anti-inflammatory
drug (NSAID) meloxicam
could help prevent interferon
dose reduction. In this study, 22
chronic hepatitis C patients
were assigned to receive 10 mg
once-daily oral meloxicam before
starting 180 mcg/week pegylated
interferon alfa-2a
(Pegasys) and continuing for
eight weeks, while 38 others
were assigned to a control
group receiving no meloxicam.
Just 9% of patients in the
meloxicam group required
Pegasys dose reduction, compared
with 45% in the control
group. The dose was lowered
due to neutropenia in 18% of
the meloxicam group versus
32% of the control group. The
researchers concluded that eight
weeks of meloxicam
“prevented dose reduction of
pegylated interferon by relieving
a decline of neutrophil count
in the treatment of chronic
hepatitis C.”
http://www.hcvadvocate.org/news/NewsUpdates_pdf/News_Review_2008/HJR-5.4.pdf
Hepatology Research, T.
Kagawa and colleagues assessed
whether the nonsteroidal
anti-inflammatory
drug (NSAID) meloxicam
could help prevent interferon
dose reduction. In this study, 22
chronic hepatitis C patients
were assigned to receive 10 mg
once-daily oral meloxicam before
starting 180 mcg/week pegylated
interferon alfa-2a
(Pegasys) and continuing for
eight weeks, while 38 others
were assigned to a control
group receiving no meloxicam.
Just 9% of patients in the
meloxicam group required
Pegasys dose reduction, compared
with 45% in the control
group. The dose was lowered
due to neutropenia in 18% of
the meloxicam group versus
32% of the control group. The
researchers concluded that eight
weeks of meloxicam
“prevented dose reduction of
pegylated interferon by relieving
a decline of neutrophil count
in the treatment of chronic
hepatitis C.”
http://www.hcvadvocate.org/news/NewsUpdates_pdf/News_Review_2008/HJR-5.4.pdf
Post Comment
Related Communities
Recent Videos
Related Expert Forums
Recent Activity
Most Popular Trackers
RSS
Expert Activity
Community Members
Popular Groups
